Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Celgene Corporation : Celgene's Profits Fall, But Focus Remains on Pipeline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2013 | 07:47pm CET

--Celgene's Q4 net falls, while revenues rise

--FDA approval decision for multiple myeloma drug Pomalyst expected in February

--Celgene shares down 2.4% to $97.64 so far this week as investors take profits

(Updates throughout adding details and analyst comment.)

 
   By Joseph Walker and Melodie Warner 
 

Celgene Corp.'s (CELG) fourth-quarter earnings fell 36% as restructuring costs and other special items hurt the drug maker's margins and masked its increased revenue.

The results had been expected since the Summit, N.J., company pre-announced full-year results for 2012 and 2013 guidance at an investor meeting earlier this month.

Celgene's revenues jumped 13% to $1.45 billion in the quarter, largely on the strength of its core blood-cancer drug franchise, which includes the blockbuster Revlimid treatment.

However, investor attention has been focused on the company's late-stage product pipeline, which includes what Celgene says are three "potential blockbusters" that would expand the company's portfolio into new disease areas.

The first of those drugs likely to reach the market is Pomalyst, a treatment for the patients with relapsed multiple myeloma, a bone marrow cancer. The U.S. Food and Drug Administration is scheduled to make an approval decision by Feb. 10. Celgene said it would launch the drug shortly after approval.

"Our commercial and medical affairs teams are ready to launch and support the thousands of patients who have exhausted all existing myeloma therapies," Celgene Executive Vice President Mark Alles said. "Successfully launching Pomalyst is a major corporate objective and we are ready."

Celgene shares fell 0.6% to $97.64, and are down 2.4% so far this week as investors take profits. Even with the recent slide, the stock has soared 24% in 2013, as investors have placed a high premium on the company's pipeline.

Celgene also plans to seek FDA approval for apremilast, a treatment for the skin disease Psoriasis, and its cancer drug Abraxane for patients with pancreatic cancer this year. Both drugs are projected to be generate billions of dollars annually for Celgene.

The new drugs are part of Celgene's strategy to expand beyond its core hematology franchise and build out new product lines in cancer to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $263.1 million, or 61 cents a share, down from $410.2 million, or 91 cents, a year earlier. Excluding items such as stock-based compensation, acquisition and restructuring costs, adjusted per-share earnings rose to $1.32 from $1.05 a year ago.

Analysts polled by Thomson Reuters had forecast earnings of $1.31 a share on revenue of $1.46 billion.

Revlimid sales jumped 17% to $1 billion, while Vidaza sales climbed 14% to $216 million.

Gross margin fell to 22.2% from 31.5% as costs rose because of preparations for the launches of Abraxane for non-small-cell lung cancer and Pomalyst. Abraxane received FDA approval for that indication in October.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
03/23 ONCOLYTICS BIOTECH : reg; Inc. Enters into First-in-Class Collaboration with Mye..
03/22 Cigna Named i4cp's Member of the Year
03/22 CELGENE : House Oversight and Government Reform Subcommittee on Health Care, Ben..
03/16 CELGENE : Oral OTEZLA® Apremilast Demonstrated Significant Improvement versus Pl..
03/15 ALLIQUA BIOMEDICAL, INC. (NASDAQ : ALQA) Files An 8-K Entry into a Material Defi..
03/14 AGIOS PHARMACEUTICALS : Announces MTAP Pathway Research Program as Development P..
03/14 CELGENE : embraces MTAP cancer deal with fast-moving collaborator Agios
03/13 AGIOS PHARMACEUTICALS, INC. (NASDAQ : AGIO) Files An 8-K Other Events
03/11 CELGENE : Regenacy Pharmaceuticals Demonstrates Reversal Of Chemotherapy-Induced..
03/09 Genentech & Bristol-Myers Squibb Dominate Franchise Image, Overall Engagement..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/20 Corporate Venture Capital - Savior Of Medtech?
03/20 Novo Nordisk - Another Apple 2013 Story? New Highs Ahead?
03/17 AMGEN TANKS ON REPATHA DATA : Analysis
03/16 CELGENE : In Breakout Mode?
Advertisement
Financials ($)
Sales 2017 13 286 M
EBIT 2017 7 280 M
Net income 2017 4 542 M
Debt 2017 3 113 M
Yield 2017 -
P/E ratio 2017 22,00
P/E ratio 2018 17,66
EV / Sales 2017 7,45x
EV / Sales 2018 6,28x
Capitalization 95 861 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 141 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION6.45%95 861
AMGEN, INC.13.56%122 281
GILEAD SCIENCES, INC.-5.75%88 214
REGENERON PHARMACEUTIC..-0.56%38 722
ACTELION LTD24.72%29 697
VERTEX PHARMACEUTICALS..20.88%22 123
More Results